Bioburden Testing of Fractional Solutions Before Sterile Filtration

Learn the bioburden testing procedure for insulin fractional solutions before sterile filtration, including sampling, membrane filtration, washing, incubation and limits.

Bioburden Testing of Fractional Solutions Before Sterile Filtration

Bioburden testing of fractional solutions is a microbiological quality-control test used to determine the number of viable microorganisms present in a solution before sterile filtration. The procedure described here applies to fractional solutions associated with insulin products and uses membrane filtration, product-specific membrane and rinsing methods, and incubation on tryptic soy agar (TSA), also referred to as soybean casein digest agar (SCD agar).

The purpose of testing before sterile filtration is to verify that the microbial load of the solution remains within the established process limit and to provide microbiological information relevant to the subsequent sterilizing-filtration step.

Direct Answer:

Bioburden testing of a fractional solution generally involves aseptically filtering a defined sample volume through a suitable membrane, washing the membrane to remove product-related antimicrobial or inhibitory effects, transferring the membrane to an appropriate culture medium, incubating it under specified conditions, and reporting the recovered microorganisms as CFU per tested volume.

What Is Bioburden Testing?

Bioburden testing is the quantitative determination of viable microorganisms present in a material, product, component, or process sample before a subsequent sterilization or microbial-control step.

In pharmaceutical manufacturing, bioburden testing is particularly important when a non-sterile solution will subsequently undergo sterilizing filtration. It helps manufacturers monitor the microbiological quality of process solutions, identify unexpected increases in microbial contamination, and support the overall microbial-control strategy.

Why Is Bioburden Testing Performed Before Sterile Filtration?

Testing before sterile filtration provides information about the microbial load entering the filtration process.

• Monitor the microbiological quality of process solutions.
• Detect unexpected increases in microbial contamination.
• Trend microbial contamination over time.
• Assess the effectiveness of upstream process controls.
• Support control of the manufacturing process.
• Provide information relevant to sterilizing-filtration performance and process validation.

Bioburden testing should be considered part of an overall microbial-control strategy and not as a replacement for sterilizing filtration or other validated sterility-assurance controls.

Scope of Fractional Solution Bioburden Testing

The procedure applies to fractional solutions of insulin products. Its stated objective is to check the bioburden of the fractional solution before sterile filtration.

Responsibilities

Activity	Responsible Personnel
Performing the test	Technical Assistant (Microbiologist) / Executive
Checking	Executive / Manager
Accountability	Head of Department

Sampling and Sample Handling

How Often Is the Fractional Solution Tested?

According to the procedure, each fraction of each insulin product is sampled for testing per month. This is a site-specific SOP requirement and should not be interpreted as a universal regulatory sampling frequency.

Sample Quantity

The procedure specifies that samples are supplied by the Parenteral Department and that the sample volume should be not less than 100 mL.

The described membrane-filtration methods use a 100 mL test volume.

Sample Preservation

If analysis cannot be performed within 8 hours after sampling, the procedure specifies storage at 2–8°C in a refrigerator.

The testing is specified to be completed within 24 hours of sampling.

Important:

Sample storage and hold-time requirements should always be controlled through the current approved laboratory SOP and validated requirements for the applicable product.

Principle of Bioburden Testing by Membrane Filtration

The membrane filtration method concentrates microorganisms present in the tested sample onto a membrane.

Sample → Membrane Filtration → Membrane Washing → Transfer to TSA/SCD Agar → Incubation → Colony Counting → CFU/100 mL

The procedure uses different membrane and washing procedures depending on the fractional solution being tested.

Product-Specific Methods for Fractional Solutions

The procedure does not use one universal filtration method for every fractional solution. Instead, different solutions are assigned to Methods A–E.

Product	Fractional Solution	Method
Mixtard	Preservative, Buffer	B
Mixtard	Preservative, Protamine & Insulin solution	D
Mixtard	Protamine solution, Preservative Buffer & Insulin Solution	D
Human Mixtard	Preservative Buffer solution	B
Human Mixtard	Preservative, Protamine & Insulin solution / Buffer & Insulin solution	D
Human Monotard	MPO solution	E
Human Monotard	Insulin solution	C
Human Monotard	NaOH solution	B
Human Monotard	Insulin, MPO & Buffer solution	C
Human Insulatard	Preservative Buffer solution	B
Human Insulatard	Preservative Protamine & Insulin solution	D
Lentard	Insulin solution	C
Lentard	Buffer solution	B
Lentard	Zn MPO solution	A
Lentard	Buffer solution	B
Actrapid	Preservative solution	B
Actrapid	Insulin solution	C
Actrapid	NaOH solution	B
Human Actrapid	NaOH solution	B

Preparation of Microbiological Plates

The procedure states that microbiological plates should be prepared according to the applicable approved SOP.

The described methods use TSA (SCD agar) as the culture medium for membrane transfer.

Important Controls Before Testing

• Use an approved culture medium.
• Verify the applicable medium quality-control status.
• Record the medium lot number.
• Correctly identify all plates.
• Maintain aseptic conditions.
• Follow the applicable microbiology laboratory SOP.

Method A: Membrane Filtration Procedure

Membrane: Nitrocellulose

1. Use the specified nitrocellulose membrane.
2. Transfer 100 mL of sample to the membrane filtration system.
3. Filter the sample immediately.
4. Wash the membrane by passing 3 × 100 mL buffer through the filter.
5. Transfer the membrane aseptically onto the surface of a TSA/SCD agar plate.

Method B: Membrane Filtration Procedure

Membrane: Durapore

1. Use the specified Durapore membrane.
2. Transfer 100 mL of sample to the membrane filter.
3. Filter the sample immediately.
4. Wash the membrane by passing 3 × 100 mL buffer through the filter.
5. Transfer the membrane to the surface of a TSA/SCD agar plate.

Method C: Membrane Filtration Procedure

Membrane: Nitrocellulose

1. Use the specified nitrocellulose membrane.
2. Filter 100 mL of sample immediately.
3. Pass 10 mL of 0.01% w/v ascorbic acid solution in 0.9% w/v NaCl through the membrane.
4. Follow with 2 × 100 mL buffer.
5. Transfer the membrane to the surface of a TSA/SCD agar plate.

Method D: Membrane Filtration Procedure

Membrane: Nitrocellulose

1. Use the specified nitrocellulose membrane.
2. Filter 100 mL of sample immediately.
3. Pass 10 mL of 0.01% w/v ascorbic acid solution in 0.9% w/v NaCl through the membrane.
4. Follow with 2 × 100 mL buffer.
5. Transfer the membrane to the surface of a TSA/SCD agar plate.

Note:

The original SOP contains inconsistent notation for the ascorbic acid concentration in this section. The preceding Method C specifies 0.01% w/v. The current approved master SOP should be verified before execution.

Method E: Membrane Filtration Procedure

Membrane: Nitrocellulose

1. Use the specified nitrocellulose membrane.
2. Filter 100 mL of sample immediately.
3. Wash the membrane using 3 × 200 mL buffer.
4. Transfer the membrane to the surface of a TSA plate.

Why Is the Membrane Washed?

Washing the membrane after filtration can be important when the product contains components capable of inhibiting microbial growth.

Potential interfering components may include:

• Preservatives
• Certain formulation ingredients
• Antimicrobial substances
• High or low pH components
• Other product constituents that can affect microbial recovery

The washing step should be part of a demonstrated and suitable microbiological method capable of recovering microorganisms from the specific product matrix.

Incubation Conditions

The procedure specifies incubation at:

30–35°C for 5 days

After incubation, bacterial and fungal colonies are counted and the result is reported as CFU/100 mL.

Bioburden Acceptance Criteria

Limit: Not more than 10 CFU/100 mL

Fungal colony: Should be absent

Important Regulatory Interpretation

The acceptance criteria above are the limits stated in the supplied SOP for this fractional-solution process. They should not be presented as universal regulatory limits for all pharmaceutical products.

Bioburden limits are established according to the applicable product, process, specification, risk assessment, pharmacopoeial requirements, validation strategy, and regulatory commitments.

How to Calculate and Report Bioburden

For the procedure described here, the result is reported as CFU/100 mL.

When exactly 100 mL is tested, the recovered colony count can be reported directly as CFU/100 mL.

Example 1: Acceptable Result

If 6 colonies are recovered from a 100 mL test volume:

Bioburden = 6 CFU/100 mL

Under the supplied SOP criterion, this result is within the stated numerical limit.

Example 2: Result Exceeding the SOP Limit

If 12 colonies are recovered from a 100 mL test volume:

Bioburden = 12 CFU/100 mL

This result exceeds the numerical limit stated in the supplied SOP and should be handled according to the applicable investigation, deviation, or OOS procedure.

Bioburden Testing vs. Sterility Testing

Feature	Bioburden Testing	Sterility Testing
Main purpose	Quantify viable microorganisms before or during processing	Assess whether viable microorganisms are detected under specified sterility-test conditions
Typical process position	Often performed before sterilization or sterilizing filtration	Usually associated with finished sterile product testing
Result	Quantitative, such as CFU/100 mL	Typically qualitative: growth/no growth
Main value	Process monitoring and microbial-load control	Part of the overall sterility-assurance strategy
Relationship to sterile filtration	Helps characterize microbial load entering filtration	Does not replace sterilizing-filter validation or aseptic-process controls

Bioburden Testing and Sterilizing Filtration

Bioburden control is closely connected with sterilizing filtration.

A sterilizing-grade filter is intended to reproducibly remove viable microorganisms from the process stream when the filtration process has been appropriately validated. Therefore, controlling and monitoring the microbial load before filtration is an important part of the overall process-control strategy.

The bioburden result should be evaluated together with the validated filtration process, filter integrity controls, environmental controls, process controls, and other applicable sterility-assurance measures.

Factors That Can Affect Bioburden Results

1. Sampling Technique

Poor sampling technique can introduce microorganisms into the sample or produce a non-representative sample.

2. Sample Holding Time

Excessive delay between sampling and testing may change the recoverable microbial population.

3. Storage Temperature

Improper sample storage can affect microbial survival and recovery.

4. Product Inhibition

Preservatives or other formulation components may suppress microbial recovery.

5. Inadequate Membrane Washing

Insufficient removal of inhibitory product components can result in low microbial recovery.

6. Excessive or Inappropriate Washing

An unsuitable washing procedure can also affect microbial recovery and method performance.

7. Aseptic Manipulation

Contamination during filtration or membrane transfer can produce falsely elevated results.

8. Culture Medium Quality

Incorrectly prepared, stored, or inadequately controlled culture media can compromise microbial recovery.

9. Incubation Conditions

Incorrect temperature, duration, or incubation conditions may influence microbial growth and colony recovery.

10. Method Suitability

The selected method should be capable of recovering microorganisms from the specific product matrix.

Practical Precautions for the Laboratory

• Perform the procedure aseptically.
• Use the membrane specified for the applicable product method.
• Verify sample identity before testing.
• Record the sample volume accurately.
• Maintain complete sample traceability.
• Use approved microbiological culture media.
• Record the medium lot number.
• Follow the specified rinse solution and volume.
• Avoid unnecessary delays during filtration.
• Prevent contamination during membrane transfer.
• Record incubation temperature and duration.
• Record colony counts clearly.
• Report results using the correct unit.
• Investigate results exceeding established limits according to the approved procedure.
• Trend bioburden results where required by the site's contamination-control strategy.

Common Mistakes in Fractional-Solution Bioburden Testing

Using the Same Method for Every Product

The procedure assigns different methods to different fractional solutions. Applying one method universally could alter microbial recovery.

Ignoring Product Inhibition

Products containing preservatives or other inhibitory ingredients may require an appropriate validated neutralization or rinsing strategy.

Treating the Bioburden Limit as Universal

The stated NMT 10 CFU/100 mL criterion belongs to the described SOP and should not automatically be applied to unrelated products.

Delaying Testing Without an Approved Hold-Time Basis

The procedure specifies defined sample-storage conditions and a maximum testing period. These requirements should be controlled through the approved laboratory procedure.

Repeating a Failed Test Without Investigation

A high result should be assessed through the applicable investigation or OOS procedure. Repeating the test without scientific justification can obscure the original result.

Confusing Bioburden With Sterility

A low bioburden does not mean that a solution is sterile. Bioburden testing measures recoverable viable microorganisms in the tested sample; sterility assurance requires a broader validated manufacturing and control strategy.

Bioburden Test Record

The supplied procedure includes an annexure for documenting the bioburden test.

Record Field	Information to Record
Name of Material	Applicable fractional solution
Batch No.	Applicable batch number
Date of Test	Date of microbiological analysis
Sampling Quantity	Actual sample volume
AR No.	Applicable laboratory reference number
Method	Membrane filtration
Slip No.	Applicable laboratory slip number
Medium	TSA/SCD agar
Medium Lot No.	Applicable culture-medium lot
Incubation Temperature	30–35°C
Incubation Period	5 days
Method No.	Applicable method number
Result	CFU/100 mL
Limit	NMT 10 CFU/100 mL; fungal colony absent according to the source SOP

Example Bioburden Test Record

Parameter	Example
Material	Fractional insulin solution
Batch No.	As applicable
Sampling Quantity	100 mL
Test Method	Membrane filtration
Membrane	According to product-specific method
Medium	TSA/SCD agar
Incubation	30–35°C for 5 days
Result	Example: 4 CFU/100 mL
SOP Limit	NMT 10 CFU/100 mL
Fungal Growth	Must meet the stated SOP criterion

Key Takeaways

• Bioburden testing measures viable microorganisms present in a pharmaceutical process sample before a microbial-control or sterilization step.
• The described procedure applies to fractional solutions associated with insulin products.
• The method uses membrane filtration followed by membrane washing and transfer to TSA/SCD agar.
• Different fractional solutions use different membrane and washing procedures identified as Methods A–E.
• The procedure specifies incubation at 30–35°C for 5 days and reporting as CFU/100 mL.
• The source SOP specifies NMT 10 CFU/100 mL and fungal colony absence as acceptance criteria.
• The stated acceptance criteria should be treated as process/SOP-specific rather than universal regulatory limits.

Frequently Asked Questions

What is bioburden testing in pharmaceuticals?

Bioburden testing is the quantitative determination of viable microorganisms present in a pharmaceutical material, product, or process sample. It is commonly used to monitor microbial control and characterize the microbial load before a subsequent sterilization or sterilizing-filtration step.

Why is bioburden tested before sterile filtration?

Bioburden is tested before sterile filtration to monitor the microbial load entering the filtration process and detect changes in upstream microbiological control. It forms part of the overall contamination-control strategy.

What method is used for bioburden testing of fractional solutions?

The described procedure uses membrane filtration. A defined sample volume is filtered through a specified membrane, the membrane is washed according to the applicable product-specific method, and it is transferred to TSA/SCD agar for incubation and colony counting.

What sample volume is used in this procedure?

The procedure specifies a 100 mL test volume for the membrane-filtration methods. The sample supplied for testing should not be less than 100 mL.

What are the incubation conditions for this bioburden test?

The described procedure specifies incubation at 30–35°C for 5 days. Results are reported as CFU/100 mL.

What is the acceptance limit for the fractional-solution bioburden test?

The supplied SOP states not more than 10 CFU/100 mL and specifies that fungal colonies should be absent. These criteria should be treated as the limits of the described SOP rather than universal limits for every pharmaceutical product.

Is bioburden testing the same as sterility testing?

No. Bioburden testing quantifies viable microorganisms present in a tested sample, whereas sterility testing assesses whether microorganisms are detected under specified sterility-test conditions. Bioburden testing does not replace a validated sterility-assurance strategy.

Why are different membrane-filtration methods used for different insulin solutions?

Different formulations can affect microbial recovery differently. The described procedure therefore assigns different membranes and/or washing procedures to specific fractional solutions. The approved method for the applicable product should always be followed.